Molecular insights on potential combination of MAPK inhibitors together with HCQ and HCQs analogs in viral infection

Tapan Kumar Mohanta1*, Nanaocha Sharma2*, Pietro Arina3,4*, Paola Defilippi5

1. Natural and Medical Sciences Research Center, University of Nizwa, Nizwa, 616, Oman,
2. Institute of Bioresources and Sustainable Development (IBSD), Imphal,795001, India
3. Department of Surgical Science, University of Turin, Turin, 10126, Italy
4. UCL Division of Medicine, Bloomsbury Institute for Intensive Care Medicine, London, WC1E 6BT, UK
5. Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, 10126, Italy

*These authors contributed equally to this study

Email: nostoc.tapan@gmail.com, sharma.nanaocha@gmail.com, pietro.arina@ucl.ac.uk & paola.defilippi@unito.it

Abstract

The outbreak of coronavirus disease-19 (COVID-19) has infected more than 11 million people and has claimed more than 530,000 deaths world-wide. In July 2020, still, there is no specific treatment for disease caused by the novel coronavirus. In the search to curb the global pandemic COVID-19, some eastern and developing countries have approved various treatment with controversial efficacy, among that the use of the antimalarial Hydroxychloroquine (HCQ), so far with inconclusive clinical evidence of effectiveness. On the other hand, computer-based screening suggest that HCQs analog are promising molecules, to impair viral replication in vitro[1]. Therefore, what is emerging from this complex background, is the need to understand molecular mechanism beyond drugs that can be helpful against viral infection for this and future pandemic. The intent of this Brief Report is to highlight: i) the involvement of the Mitogen Activated Protein Kinase (MAPK) cascade in viral infection and ii) the urgent need to have molecular data on the effectiveness of the combination of MAPK inhibitors together with HCQ and HCQs analogs in curbing viral infection. We are convinced that a better understanding of the patterns of elicited molecular mechanisms will be critical for new molecular approaches to this severe disease.
Introduction

Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2)-mediated CoVid19 is a global pandemic that has infected more than 11 million people and has claimed more than 530,000 lives worldwide. During the global crisis such as that due to CoVid19, the need to discover new drugs or to repositioning old medicines for new uses is urgent. In June 2020, still, there is no specific treatment for disease caused by the novel coronavirus, but many specific treatments are under investigation, among those Remdesivir, a nucleotide analogue of adenosine 5-monophosphate with antiviral activity against hepatitis B virus (HBV) and human immunodeficiency virus (HIV), Tocilizumab (TCZ) a humanized monoclonal antibody anti interleukin-6-receptor (IL-6R), or convalescent plasma or immunoglobulins.

MAPKs are highly conserved serine-threonine protein kinases that link cell-surface receptors to transcription factors, transducing extracellular signals into various outputs, which may also impact on host defence and apoptosis. The MAPK cascade includes Extracellular Signal-Regulated Kinase (ERK1/2), p38, and c-Jun NH2-terminal kinase (JNK), with each MAPK signalling pathway consisting of at least three components, a MAPK kinase kinase (MAP3K), a MAPK kinase (MAP2K), and a MAPK[2]. The membrane proximal upstream kinase Raf-1 is activated by the small GTPase Ras, which is triggered by the canonical receptor tyrosine kinase (RTK)-Grb2-SOS signalling scheme[3]. Members of the Ras family of proteins, including K-Ras, H-Ras, and N-Ras, play a key role in transmission of extracellular signals into the cells[4]. Since decades, intense work is under way to develop and evaluate compounds that target components of MAPK pathways, for the treatment of inflammatory and neurodegenerative diseases, and of cancer[5],[6],[7].

CQ (N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) has long been used to treat malaria and amebiasis. Hydroxychloroquine (HCQ) sulfate is one of its derivatives, demonstrated to be at least 40% less toxic than CQ in animals[8], and it is still widely available for treatment of autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis. HCQ has shown potential to modulate COVID19 disease[9],[10], suggesting its prophylactic use against coronavirus[11]. Very recently, mefloquine, a quinoline-derivative belonging to the same class of antimalaria agents of CQ and HCQ, has been reported for their effects on ACE2 maturation[12]. Computer-based screening suggest that HCQs analogues are promising molecules to impair viral replication in vitro[12]. However, to date, there are no clear data indicating that HCQ has a favourable effect on outcomes in patients with COVID-
Several randomized controlled trials under way use both chloroquine and HCQ as prophylaxis, postexposure prophylaxis, and in treatment regimens. Increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies. Informative data from the COVID-19 Global Rheumatology Registry, a registry of COVID-19 rheumatology patients, will also help understand characteristics and outcomes in patients already taking disease-modifying and immunosuppressive medication [13]. Overall, in our opinion, at least two main issues to be rapidly solved are: i) in the clinic, due to the absence of a commonly agreed dosing protocol based on pharmacokinetic considerations, the dose and treatment duration for hydroxychloroquine (HCQ) COVID-19 disease currently vary across national guidelines and clinical study protocols [14]; (ii) in the basic science, the urgent need of detailed molecular and biological studies on HCQ and derivatives in the context of COVID-19 infection by in vitro and in vivo assays. Therefore, the intent of this Brief Report is to highlight the impact on the Mitogen Activated Protein Kinase (MAPK) cascade on the viral infection, to propose that combinatorial approaches targeting MAPK cascade together with HCQ derivatives can represent new generation antivirals. Basic molecular studies deserve further investigation, in that they may lead to new strategies controlling the replication of several viruses.

**The MAPK cascade in viral infections**

It is already well known that the MAPK pathways may be altered/involved in viral infection, as a cellular signalling pathways exploited by viruses for their own effective replication, translation, transport across nuclear membrane as well as capsid assembly, and spreading, as well reactivation of virus latency [15]. Interestingly, MAPK cascade also participate in regulating immune response [16] and apoptosis [17] in virus infected cells. A variety of DNA and RNA viruses induce signalling through MAP kinase cascades in infected host cells [18], [19]. MAPK signalling may either act as positive or negative regulator of viral replication, exploiting exogenous activator of the MAPK pathway, such as G-protein linked or tyrosine kinase receptors to promote their own replication [20]. MAPK pathways can be active upon both live or inactivated virus cell contact [20], and even viral secretory proteins can trigger ERK1/2 activation, likely due to the homology of viral proteins with Epidermal Growth Factor (EGF) and Transforming Growth Factor (TGF) [21]. Host factors may either support (proviral effect) or inhibit (antiviral effect) viral replication. The proviral factors may serve as targets for development of antiviral therapeutics [15]. Indeed, such widespread use of MAPK cascade by viruses suggests that this pathway may be targetable for developing broad-spectrum antiviral therapeutics.
antiviral drugs. Several viruses can be sensitive to MAPK kinase inhibitor, that may have potential to act as antiviral agents, as summarized in[15]. Interestingly, drugs targeting the Raf-MAPK signalling pathways through the use of the p38 MAPK inhibitor, SB203580, inhibited effectively phosphorylation of HSP-27, CREB, and eIF4E in SARS-CoV-infected cells, as a promising new class of antiviral agents [22].

Influenza A viruses, a relevant world-wide pathogen group both in humans and different animals, causes a biphasic activation of the Raf/MEK/ERK1/2 cascade inhibited by treatment with the MEK inhibitor U0126. Inhibition of Raf signalling causes nuclear retention of viral ribonucleoprotein complexes (RNPs), impaired function of the nuclear-export protein (NEP/NS2), and concomitant inhibition of virus production. Overall, signalling through the MAPK pathway may play a key role in virus production and RNP export from the nucleus during the viral life cycle[23]. U0126 also interferes with spreading of Borna Disease Virus (BDV) to neighbouring cells, impacting on BDV-host cell interaction[24]. MAPKs including ERK1/2, JNK, and p38, play a crucial role in infection of coronaviruses, such as mouse hepatitis virus and SARS-CoV[25],[26], while the ER-stress caused by Japanese Encephalitis virus infection induces the activation of p38 mitogen-activated protein kinase (MAPK) and host cell apoptosis [27].

Moreover, the inhibition of ERK1/2 and of p38 MAPK pathway is also associated with the signalling cascade that leads to the decline in the Varicella Zoster viral progeny[28]. ERK1/2 cascade is partially activated during Varicella Zoster virus infection and contributes to the induction of cell-survival signals. In this example, for instance, c-Raf was not active, whereas its downstream kinases MEK1/2 and ERK1/2 were transiently phosphorylated. Inhibition of this signal cascade impaired virus replication and increased the apoptotic response, through the suppressed phosphorylation of Bad, a cell-death regulator and a cytosolic indirect target of ERK1/2. New insights into the molecular basis of viral hepatitis reveal that three of these agents – the hepatitis B, which infects more than 300 million people world-wide and is a common cause of liver disease and liver hepatocellular carcinoma (HCC), C, and E viruses (HBV, HCV and HEV) modulate the mitogen-activated protein kinase (MAPK) signalling pathway[28]. Dysregulation of signalling mechanisms such as ERK1/2 are known to promote several different stages of HBV infection. Among them, the HBxAg protein exerts multiple functions, including signal transduction, transcriptional activation, DNA repair, and inhibition of protein degradation. HBxAg directly activates the MAPK-ERK pathway through the activation of Ras, leading to cell progression into the S phase through the upregulation of cyclin D1[28]. Overall,
these data open new avenues with respect to antiviral drug development. On the other hand, inhibition of cyclin dependent kinase (CDK1, CDK2, and CDK5) significantly reduces the replication of viruses as well[29] and the higher expression of CDK1 and CDK2 leads to the reactivation of the herpes virus [30]. Interestingly, inhibiting Raf associated MEK-ERK1/2 results in lowering the reactivation of Kaposi’s sarcoma associated herpes virus [31],[32],[33].

**Can CQ and HCQ impact on MAPK activation?**

So far, there are sufficient data in the literature about the possible mechanisms of action of both CQ and HCQ drugs in human cells, that can be exploited for addressing their action against viral infection. A very recent update on human coronavirus receptors/co-receptors as possible targets for CQ-induced inhibition of the virus replication cycle has been recently published [34]. Both CQ and HCQ are weak bases that can elevate the pH of acidic intracellular organelles, such as endosomes/lysosomes, essential for membrane fusion. Indeed, CQ mainly impairs autophagy by interfering with autophagosome fusion with lysosomes rather than affecting the acidity and/or degradative activity of this organelle[35]. In addition, CQ could inhibit SARS-CoV-2 entry through changing the glycosylation of angiotensin-converting enzyme 2 (ACE2) receptor and spike protein[36], as also suggested for HCQ analogues[1].

Digging into the previously published literature of mechanism of action of HCQ revealed its possible role through the action of MAPK pathway[37]. Addressing the CQ and HCQ mechanisms on the MAPK cascade, CQ can affect the activation of p38 MAPK and cytokine production caused by bacterial CpG DNA [38], as well as ERK1/2 is also affected by virus infection and CQ[23],[37]. In peripheral blood PMBC, CQ reduced the phosphorylation event of ERK1/2 through blocking the phosphorylation event of mitogen activated protein/ERK kinase (MEK)[37]. Interestingly, the CQ inhibitory mechanism was different from that of the classical MEK pathway inhibitor PD98059, as CQ treatment resulted in deactivation of the upstream regulatory activator Raf. Moreover, they also showed that CQ treatment restored HeLa cells sensitivity to anti-Fas-mediated apoptosis in a manner similar to PD98059 sensitivity that is lost when ERK activation is interrupted in this cell line[39]. Consistent with these data, a correlation between CQ and the impaired activation of p38 MAPK, and ERK1/2 in human coronavirus 229E (HCoV-229E) infection of human epithelial lung cells, have been shown, demonstrating their involvement in the replication of HCoV-229E[40].

The MAPK pathways is also required for the production of tumour necrosis factor alpha (TNF-alpha)[37]. The application of CQ, as well as MAPK inhibitor PD98059 leads to inhibition of
lipopolysaccharide (LPS)-induced MAPK activation and TNF-alpha expression in the human THP-1 and murine AMJ2C-8 macrophage cell lines, but not in RAW264.7 cells, that does not require MEK-ERK signalling for TNF-alpha production[37],[15]. These were the first hints on the ability of CQ of profoundly affecting both signalling and expression of inflammatory cytokines. CQ was also effective in reducing lipopolysaccharide (LPS)-induced IL-1 beta release in THP-1 cells at transcriptional level and strongly inhibited phosphorylation of p38 MAPK, and to a lesser extent c-Jun N-terminal kinase and ERK1/2[41]. Overall, these results show that therapeutic concentrations of CQ may interfere with MAPK pathways activation at different levels through a still partially unexplored mechanism, which can also impact, at least in part, on the observed anti-inflammatory response to this drug.

The complexity of the mechanisms of action of MAPK cascade associated with the viral activation and progeny can be highly correlated with the mechanism of action of CQ. As shown above, in the model of HCoV-229 coronavirus, CQ-induced virus inhibition occurs through inhibition of p38 MAPK[40]. Therefore, HCQ treatment can directly impact the replication of viral progeny through the inhibition of MAPK pathway. Simultaneously, the reactivation of viral infection can also be inhibited by HCQ through the inhibition of ERK-MEK1/2 signalling cascade. Mice studies are still controversial. The only viral disease where CQ was effective so far before COVID-19 era was chronic hepatitis C, suggesting an increased virological response to pegylated interferon plus ribavirin[42]. However, these drugs are of low cost, reasonably safe, and widely available in low-income countries where other pathologies like malaria are endemic[15], to be proposed as a prophylactic treatment.

**MAPK activation in severe COVID-19 disease**

The epidemiology of COVID19 has not yet been fully understood. It has been estimated that the number of positive people can be many times higher than the numbers available to us, with countries, such as Italy, with 10 times the estimated positive compared to the real ones. A continuous stream of new information arrives each day about COVID-19 statistics and data to date suggest that 80% of the cases are mild or asymptomatic, 15% are severe infection, requiring oxygen and 5% are critical infections, requiring ventilation (WHO report 46).

Moreover, COVID19 severe illness is more common in people who have other health problems, particularly the elderly, those with cardiovascular disease, chronic lung disease and hypertension[43]. People with diabetes are among those high-risk categories that can have serious illness if they get the virus[44]. In diabetic mellitus (DM), the MAPK cascade exerts a
regulatory role in pancreatic islet beta-cell in mediating the cellular responses to excessive generation of intracellular ROS (oxidative stress). Additionally, novel pharmacological agents targeting MAPK have potential to improve beta-cell function in diabetes[45]. Moreover, upon insulin uptake by the endothelial barrier that mediate insulin’s actions in muscle, heart, fat, and the brain, the MAPK pathway enhances the expression of ET-1 and PAI-1 and migration and proliferation of contractile cells, which have proatherogenic actions. In insulin resistance or deficiency and in diabetes, there is a loss of insulin’s antiatherogenic actions via IRS/PI3K/Akt cascade, all of which leads to the acceleration of atherosclerosis. In contrast the activated MAPK pathway still has pro-atherosclerotic actions[46]. MAPK is also essential in mediating the pathogenesis of renal growth seen in early DM. In a model of DM rats, Erk1/2 MAPK level and activity in glomeruli is highly increased, also due to the loss of MAPK phosphatase-1, a dual specificity phosphatase that inactivates MAPK[47], with a strong implication in the pathogenesis of DM nephropathy. it is thus tempting to speculate that diabetic patients are more prone to CoVid19 infection and subsequent death also due to the activation of MAPK pathway upon viral activation and progeny [48],[33],[31]. Moreover, the existing data on the down-regulation of MAPK pathway activity upon CQ and HCQ treatment, can be taken in account, mainly on the severity of the COVID19 disease in patients with additional health problems. Application of CQ can control the glucose metabolism in DM patient as well[49],[50]. Thus, application of CQ in DM patient can improve the glucose metabolism and down regulate the MAPK pathway which could contribute to dampen the viral activation and progeny.

The MAPK cascade is a master regulator of cell proliferation in cancer. Application of CQ and HCQ has long been studied against cancer[51], [52],[52]. A combination of ERK and autophagy inhibition was useful towards treatment of the pancreatic cancer[53]. Inhibition of ROS mediated MEK/ERK pathway induces breast cancer cell death and autophagy[54]. Elicitation of autophagy via inhibition of MEK/ERK pathway proven to be strategy for treatment of RAS-driven cancers[55]. CQ increases antioestrogen responsiveness in resistant tumour cells through the inhibition of autophagy and it has suggested to use CQ as an adjuvant to anti- cancer chemotherapy[56],[57]. It is also well known that lymphocytes play an important role in maintaining immune homeostasis and inflammatory response in our body, particularly relevant in cancer patients. It has also shown that ACE2 expression is high in lymphocytes in oral mucosa[58]. In the recent work, it is shown that the percentage of blood lymphocyte showed the most significant and consistent reduction trend among the COVID19 positive patients, suggesting that lymphopenia could be a predictor of prognosis among
COVID-19 patients[59]. Since it has been well known that CQ inhibit the MEK/ERK pathway in human, the inhibition of MEK/ERK1/2 pathway via CQ-mediated treatment can be further investigated as a boon and double benefit for the CoVid19 patients suffering with cancer problems.

Many patients around the world have been already treated with these drugs in this pandemic situation. The data presented here outline that the MAPK cascade, which, in turn, is a key pathway in regulating different steps of viral replication, transport, translation, capsid assembly, and spreading, may be affected at some levels by CQ and HCQ treatment. Moreover, MAPK may also control inflammatory cytokine production and cellular apoptosis upon viral infection, integrating signals from complex intracellular networks in performing cellular functions, thus being a rather obvious target to fight against viral infection. Due to the initial discovery of the core elements of the MAPK pathways nearly four decades ago, considerable effort has been focused on development of MAPK inhibitors which have shown promising clinical responses in cancer patients, both as single inhibitors or in combination[7]. The pandemic crisis imposes to think about high-throughput molecular approaches to moving from operational to scientifically-driven pharmacovigilance. Common challenges, including advancements in modern technologies and in data quality to strengthen translational science are needed. Therefore, it is tempting to speculate that combinatorial approaches with low dose of both MAPK inhibitors and CQ or HCQ are needed to set optimal conditions, i.e. computing the Combination Index (CI) values or the different combinations of drugs in all the experimental settings. Moreover, more basic science is required for a better understanding of each individual drug’s mechanism of action, and to identify the key molecular signalling mechanisms involved.

To this end, both automatized platforms for cell viability/apoptosis assays, and genome-wide siRNA screens and/or CRISPR-CAS9 technology are largely available. Of note, genome wide siRNA screens conducted on SARS-CoV6[60] have identified MNK1 as one of the cellular factors that regulate virus replication. More detailed functional analyses of these host genes (identified in genome-wide screens) will provide insights for development of novel antiviral therapeutics.

Conclusions

Overall, the number of COVID-19 cases represents only the point of an iceberg, since apparently from 60-80% of the infected people are asymptomatic. The epidemiological classical measures of social distancing in all the world have reduced the overload of hospitals
and intensive therapies but the numbers are still confirmed that the infection curve is not at all under control and the risk of a new surge of cases in the next months is always lurking. Therefore, understanding the MAPK cascade mechanisms in sustaining infection may be relevant for this pandemic. Moreover, any knowledge we can add to the correlation between MAPK cascade and HCQ could pave the way to new molecular approaches to this severe disease, keeping always in mind that a systematic strategy is needed for pre-clinical optimization of drugs to serve at risk population.

Acknowledgements

This work was supported by MIUR (Ministero Università Ricerca, PRIN 2015 to PD), AIRC (Associazione Italiana Ricerca Cancro) to PD (IG-20107), Compagnia San Paolo, Torino, Progetto DEFLECT to PD; Fondazione CRT 2017.2954 to PD. TKM and NS would like to extend their sincere thanks to the Natural and Medical Sciences Research Center, University of Nizwa, Nizwa, 616, Oman, Department of Biotechnology, Govt. of India and Institute of Bioresources and Sustainable Development (IBSD), Imphal for their necessary support. PA would like to thank the School of Anaesthesia, Resuscitation, Intensive Care and Palliative Care of Turin, to let him continue his formation at UCL, London and Prof. Mervyn Singer, UCL, London, for his suggestions and his optimism.

Conflict of interest

There is no competing of interest to declare

References

1. Boldrini, A.; Terruzzi, L.; Spagnolli, G.; Astolfi, A.; Massignan, T.; Lolli, G.; Barreca, M. L.; Biasini, E.; Faccioli, P.; Pieri, L. Identification of a Druggable Intermediate along the Folding Pathway of the SARS-CoV-2 Receptor ACE2. 2020, 2, 1–19.

2. Kim, E. K.; Choi, E.-J. Pathological roles of MAPK signaling pathways in human diseases. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2010, 1802, 396–405, doi:https://doi.org/10.1016/j.bbdis.2009.12.009.

3. Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in
cancer. *Oncogene* **2007**, *26*, 3279–3290, doi:10.1038/sj.onc.1210421.

4. Malumbres, M.; Barbacid, M. RAS oncogenes: the first 30 years. *Nature Reviews Cancer* **2003**, *3*, 459–465, doi:10.1038/nrc1097.

5. Degirmenci, U.; Wang, M.; Hu, J. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. *Cells* **2020**, *9*, doi:10.3390/cells9010198.

6. Lu, S.; Jang, H.; Muratcioglu, S.; Gursoy, A.; Keskin, O.; Nussinov, R.; Zhang, J. Ras Conformational Ensembles, Allostery, and Signaling. *Chemical Reviews* **2016**, *116*, 6607–6665, doi:10.1021/acs.chemrev.5b00542.

7. Shin, M. H.; Kim, J.; Lim, S. A.; Kim, J.; Lee, K. M. Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade. *International journal of molecular sciences* **2020**, *21*, doi:10.3390/ijms21072531.

8. McChesney, E. W. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. *The American Journal of Medicine* **1983**, *75*, 11–18, doi:https://doi.org/10.1016/0002-9343(83)91265-2.

9. Liu, J.; Cao, R.; Xu, M.; Wang, X.; Zhang, H.; Hu, H.; Li, Y.; Hu, Z.; Zhong, W.; Wang, M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discovery* **2020**, *6*, 16, doi:10.1038/s41421-020-0156-0.

10. Singh, A. K.; Singh, A.; Shaikh, A.; Singh, R.; Misra, A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* **2020**, *14*, 241–246, doi:https://doi.org/10.1016/j.dsx.2020.03.011.

11. Principi, N.; Esposito, S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. *The Lancet Infectious Diseases* **2020**, doi:https://doi.org/10.1016/S1473-3099(20)30296-6.

12. Fan, H. H.; Wang, L. Q.; Liu, W. L.; An, X. P.; Liu, Z. D.; He, X. Q.; Song, L. H.; Tong, Y. G. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. *Chinese medical journal* **2020**, doi:10.1097/CM9.0000000000000797.
13. Palca, J. Libya gets unwelcome visitor from the West. *Science* **1990**, *249*, 117 LP – 118, doi:10.1126/science.2371558.

14. Thémans, P.; Dauby, N.; Schrooyen, L.; Lebout, F.; Delforge, M.; Nasreddine, R.; Libois, A.; Payen, M.-C.; Konopnicki, D.; Wuillaume, F.; Lescrainier, C.; Verlinden, V.; Dogné, J.-M.; Hamdani, J.; Musuamba, F. T. Model informed dosing of Hydroxychloroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and Gaps. *British Journal of Clinical Pharmacology* **2020**, n/a, doi:10.1111/bcp.14436.

15. Kumar, R.; Khandelwal, N.; Thachamvally, R.; Tripathi, B. N.; Barua, S.; Kashyap, S. K.; Maherchandani, S.; Kumar, N. Role of MAPK/MNK1 signaling in virus replication. *Virus Research* **2018**, *253*, 48–61, doi:https://doi.org/10.1016/j.virusres.2018.05.028.

16. Gaur, P.; Munjal, A.; Lal, S. K. Influenza virus and cell signaling pathways. *Medical Science Monitor* **2011**, *17*, 148–154, doi:10.12659/MSM.881801.

17. Bian, J.; Wang, K.; Kong, X.; Liu, H.; Chen, F.; Hu, M.; Zhang, X.; Jiao, X.; Ge, B.; Wu, Y.; Meng, S. Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus. *Archives of Virology* **2011**, *156*, 1335–1344, doi:10.1007/s00705-011-0987-y.

18. Bruder, J. T.; Kovesdi, I. Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. *Journal of Virology* **1997**, *71*, 398–404.

19. Popik, W.; Hesselgesser, J. E.; Pitha, P. M. Binding of Human Immunodeficiency Virus Type 1 to CD4 and CXCR4 Receptors Differentially Regulates Expression of Inflammatory Genes and Activates the MEK/ERK Signaling Pathway. *Journal of Virology* **1998**, *72*, 6406–6413.

20. Rodríguez, M. E.; Brunetti, J. E.; Wachsman, M. B.; Scolaro, L. A.; Castilla, V. Raf/MEK/ERK pathway activation is required for Junín virus replication. *Journal of General Virology* **2014**, *95*, 799–805, doi:10.1099/vir.0.061242-0.

21. Andrade, A.; Silva, P.; Pereira, A.; Sousa, L.; Ferreira, P.; Gazzinelli, R.; Kroon, E.; Ropert, C.; Bonjardim, C. The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication. *The Biochemical journal*
22. Mizutani, T.; Fukushima, S.; Saijo, M.; Kurane, I.; Morikawa, S. Importance of Akt signaling pathway for apoptosis in SARS-CoV-infected Vero E6 cells. *Virology* **2004**, *327*, 169–174, doi:https://doi.org/10.1016/j.virol.2004.07.005.

23. Pleschka, S.; Wolff, T.; Ehrhardt, C.; Hobom, G.; Planz, O.; Rapp, U. R.; Ludwig, S. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. *Nature Cell Biology* **2001**, *3*, 301–305, doi:10.1038/35060098.

24. Planz, O.; Pleschka, S.; Oesterle, K.; Berberich-Siebelt, F.; Ehrhardt, C.; Stitz, L.; Ludwig, S. Borna Disease Virus Nucleoprotein Interacts with the Cdc2-Cyclin B1 Complex. *Journal of Virology* **2003**, *77*, 11186–11192, doi:10.1128/JVI.77.20.11186-11192.2003.

25. Banerjee, S.; Narayanan, K.; Mizutani, T.; Makino, S. Murine Coronavirus Replication-Induced p38 Mitogen-Activated Protein Kinase Activation Promotes Interleukin-6 Production and Virus Replication in Cultured Cells. *Journal of Virology* **2002**, *76*, 5937–5948, doi:10.1128/JVI.76.12.5937-5948.2002.

26. Kopecky-Bromberg, S. A.; Martinez-Sobrido, L.; Frieman, M.; Baric, R. A.; Palese, P. Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame (ORF) 3b, ORF 6, and Nucleocapsid Proteins Function as Interferon Antagonists. *Journal of Virology* **2007**, *81*, 548–557, doi:10.1128/JVI.01782-06.

27. Su, H.-L.; Liao, C.-L.; Lin, Y.-L. Japanese Encephalitis Virus Infection Initiates Endoplasmic Reticulum Stress and an Unfolded Protein Response. *Journal of Virology* **2002**, *76*, 4162–4171, doi:10.1128/JVI.76.9.4162-4171.2002.

28. Panteva, M.; Korkaya, H.; Jameel, S. Hepatitis viruses and the MAPK pathway: is this a survival strategy? *Virus Research* **2003**, *92*, 131–140, doi:https://doi.org/10.1016/S0168-1702(02)00356-8.

29. Schang, L. M.; Rosenberg, A.; Schaffer, P. A. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. *Journal of virology* **1999**, *73*, 2161–2172.

30. Schang, L. M.; Bantly, A.; Schaffer, P. A. Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear cdk2 and cdk4. *Journal of virology*
31. Traylen, C. M.; Patel, H. R.; Fondaw, W.; Mahatme, S.; Williams, J. F.; Walker, L. R.; Dyson, O. F.; Arce, S.; Akula, S. M. Virus reactivation: A panoramic view in human infections. *Future Virology* 2011, 6, 451–463, doi:10.2217/fvl.11.21.

32. Yu, F.; Harada, J. N.; Brown, H. J.; Deng, H.; Song, M. J.; Wu, T.-T.; Kato-Stankiewicz, J.; Nelson, C. G.; Vieira, J.; Tamanoi, F.; Chanda, S. K.; Sun, R. Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus. *PLoS pathogens* 2007, 3, e44–e44, doi:10.1371/journal.ppat.0030044.

33. Xie, J.; Ajibade, A. O.; Ye, F.; Kuhne, K.; Gao, S.-J. Reactivation of Kaposi’s sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. *Virology* 2008, 371, 139–154, doi:10.1016/j.virol.2007.09.040.

34. Devaux, C. A.; Rolain, J.-M.; Colson, P.; Raoult, D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? *International Journal of Antimicrobial Agents* 2020, 105938, doi:https://doi.org/10.1016/j.ijantimicag.2020.105938.

35. Mauthe, M.; Orhon, I.; Rocchi, C.; Zhou, X.; Luhr, M.; Hijlkema, K.-J.; Coppers, R. P.; Engedal, N.; Mari, M.; Reggiori, F. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. *Autophagy* 2018, 14, 1435–1455, doi:10.1080/15548627.2018.1474314.

36. Savarino, A.; Di Trani, L.; Donatelli, I.; Cauda, R.; Cassone, A. New insights into the antiviral effects of chloroquine. *The Lancet Infectious Diseases* 2006, 6, 67–69, doi:https://doi.org/10.1016/S1473-3099(06)70361-9.

37. Weber, S. M.; Chen, J.-M.; Levitz, S. M. Inhibition of Mitogen-Activated Protein Kinase Signaling by Chloroquine. *The Journal of Immunology* 2002, 168, 5303–5309, doi:10.4049/jimmunol.168.10.5303.

38. Kirsch, J.; Krieg, A. M. CpG DNA activate leukocytes through pH-dependent generation of reactive oxygen species. *Free Radical Biology and Medicine* 1998, 25, S55, doi:10.1016/s0891-5849(98)90168-x.

39. Holmström, T. H.; Tran, S. E. F.; Johnson, V. L.; Ahn, N. G.; Chow, S. C.; Eriksson, J.
E. Inhibition of Mitogen-Activated Kinase Signaling Sensitizes HeLa Cells to Fas Receptor-Mediated Apoptosis. *Molecular and Cellular Biology* **1999**, *19*, 5991–6002, doi:10.1128/mcb.19.9.5991.

40. Kono, M.; Tatsumi, K.; Imai, A. M.; Saito, K.; Kuriyama, T.; Shirasawa, H. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERK. *Antiviral Research* **2008**, *77*, 150–152, doi:https://doi.org/10.1016/j.antiviral.2007.10.011.

41. Seitz, M.; Valbracht, J.; Quach, J.; Lotz, M. Gold Sodium Thiomalate and Chloroquine Inhibit Cytokine Production in Monocytic THP-1 Cells Through Distinct Transcriptional and Posttranslational Mechanisms. *Journal of Clinical Immunology* **2003**, *23*, 477–484, doi:10.1023/B:JOCI.0000010424.41475.17.

42. Palumbo, E. Pegylated interferon and ribavirin treatment for hepatitis C virus infection. *Therapeutic Advances in Chronic Disease* **2011**, *2*, 39–45, doi:10.1177/2040622310384308.

43. Jordan, R. E.; Adab, P.; Cheng, K. K. Covid-19: risk factors for severe disease and death. *BMJ* **2020**, *368*, doi:10.1136/bmj.m1198.

44. AmericanDiabetesAssociation How COVID-19 Impacts People with Diabetes. *American Diabetes Association* **2020**, https://www.diabetes.org/coronavirus-covid-19/how-.

45. Sidarala, V.; Kowluru, A. The Regulatory Roles of Mitogen-Activated Protein Kinase (MAPK) Pathways in Health and Diabetes: Lessons Learned from the Pancreatic β-Cell. *Recent Patents on Endocrine, Metabolic & Immune Drug Discovery* **2016**, *10*, 76–84, doi:10.2174/1872214810666161020154905.

46. King, G. L.; Park, K.; Li, Q. Selective insulin resistance and the development of cardiovascular diseases in diabetes: The 2015 Edwin Bierman Award Lecture. *Diabetes* **2016**, *65*, 1462–1471, doi:10.2337/db16-0152.

47. Xu, Z.; Sun, J.; Tong, Q.; Lin, Q.; Qian, L.; Park, Y.; Zheng, Y. The role of ERK1/2 in the development of diabetic cardiomyopathy. *International Journal of Molecular Sciences* **2016**, *17*, 1–17, doi:10.3390/ijms17122001.

48. Rahaus, M.; Desloges, N.; Wolff, M. H. Varicella-zoster virus influences the activities
of components and targets of the ERK signalling pathway. *Journal of General Virology* **2006**, *87*, 749–758, doi:https://doi.org/10.1099/vir.0.81571-0.

49. Powrie, J. K.; Smith, G. D.; Shojaee-Moradie, F.; Sonksen, P. H.; Jones, R. H. Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. *American Journal of Physiology-Endocrinology and Metabolism* **1991**, *260*, E897–E904, doi:10.1152/ajpendo.1991.260.6.E897.

50. Hage, M. P.; Al-Badri, M. R.; Azar, S. T. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. *Therapeutic advances in endocrinology and metabolism* **2014**, *5*, 77–85, doi:10.1177/2042018814547204.

51. Viswas, R.; Lee, H. Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies. *European journal of pharmacology* **2009**, *625*, 220–233, doi:10.1016/j.ejphar.2009.06.063.

52. Verbaanderd, C.; Maes, H.; Schaaf, M. B.; Sukhatme, V. P.; Pantziarka, P.; Sukhatme, V.; Agostinis, P.; Bouche, G. Repurposing drugs in oncology (ReDO) - Chloroquine and hydroxychloroquine as anti-cancer agents. *Ecancermedicalscience* **2017**, *11*, 1–35, doi:10.3332/ecancer.2017.781.

53. Bryant, K. L.; Stalnecker, C. A.; Zeitouni, D.; Klomp, J. E.; Peng, S.; Tikunov, A. P.; Gunda, V.; Pierobon, M.; Waters, A. M.; George, S. D.; Tomar, G.; Papke, B.; Hobbs, G. A.; Yan, L.; Hayes, T. K.; Diehl, J. N.; Goode, G. D.; Chaika, N. V.; Wang, Y.; Zhang, G.-F.; Witkiewicz, A. K.; Knudsen, E. S.; Petricoin 3rd, E. F.; Singh, P. K.; Macdonald, J. M.; Tran, N. L.; Lyssiotis, C. A.; Ying, H.; Kimmelman, A. C.; Cox, A. D.; Der, C. J. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. *Nature medicine* **2019**, *25*, 628–640, doi:10.1038/s41591-019-0368-8.

54. Hung, A. C.; Tsai, C.-H.; Hou, M.-F.; Chang, W.-L.; Wang, C.-H.; Lee, Y.-C.; Ko, A.; Hu, S. C.-S.; Chang, F.-R.; Hsieh, P.-W.; Yuan, S.-S. F. The synthetic β-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway. *Cancer Letters* **2016**, *371*, 251–261, doi:https://doi.org/10.1016/j.canlet.2015.11.035.

55. Kinsey, C. G.; Camolotto, S. A.; Boespflug, A. M.; Guillen, K. P.; Foth, M.; Truong, A.; Schuman, S. S.; Shea, J. E.; Seipp, M. T.; Yap, J. T.; Burrell, L. D.; Lum, D. H.;
Whisenant, J. R.; Gilcrease, G. W.; Cavalieri, C. C.; Rehbein, K. M.; Cutler, S. L.; Affolter, K. E.; Welm, A. L.; Welm, B. E.; Scaife, C. L.; Snyder, E. L.; McMahon, M.
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. *Nature Medicine* **2019**, *25*, 620–627, doi:10.1038/s41591-019-0367-9.

56. Cook, K. L.; Wärri, A.; Soto-Pantoja, D. R.; Clarke, P. A. G.; Cruz, M. I.; Zwart, A.; Clarke, R. Chloroquine Inhibits Autophagy to Potentiate Anti-estrogen Responsiveness in ER+ Breast Cancer. *Clinical Cancer Research* **2014**, *20*, 3222 LP – 3232, doi:10.1158/1078-0432.CCR-13-3227.

57. Pascolo, S. Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies. *European Journal of Pharmacology* **2016**, *771*, 139–144, doi:https://doi.org/10.1016/j.ejphar.2015.12.017.

58. Xu, H.; Zhong, L.; Deng, J.; Peng, J.; Dan, H.; Zeng, X.; Li, T.; Chen, Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *International Journal of Oral Science* **2020**, *12*, 8, doi:10.1038/s41368-020-0074-x.

59. Tan, L.; Wang, Q.; Zhang, D.; Ding, J.; Huang, Q.; Tang, Y.-Q.; Wang, Q.; Miao, H. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. *Signal Transduction and Targeted Therapy* **2020**, *5*, 33, doi:10.1038/s41392-020-0148-4.

60. de Wilde, A. H.; Wannee, K. F.; Scholte, F. E. M.; Goeman, J. J.; ten Dijke, P.; Snijder, E. J.; Kikkert, M.; van Hemert, M. J. A Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway Proteins. *Journal of Virology* **2015**, *89*, 8318–8333, doi:10.1128/jvi.01029-15.